Skip to content

Released Aug 8, 2024, after the close

10-Q filed Aug 8, 2024, 39 days after period end · 0000950170-24-093998

Q2 2024 · 10-Q
Revenue$8.53M— vs Q2 2023+47.5% vs Q1 2024
Net Income-$11.15MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$1.98N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$12,203,000N/M
Operating Cash Flowderived-$17,102,000N/M
Free Cash Flowderived-$17,116,000N/M
Margins · derived
Operating margin-143.0%
Net margin-130.7%

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$8.53M$0.00——
Net Income-$11.15M-$16.90M-$24.46M-$23.60M
EPS Diluted-$1.98-$3.88-$0.51-$0.55

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR